Gov. Kristi Noem, a Republican, signed an executive order Tuesday restricting the use of abortion drugs in South Dakota.
“The Biden administration is continuing to overstep its authority and suppress legislatures that are standing up for the unborn to pass strong pro-life laws,” Noem said in a statement. “They are working right now to make it easier to end the life of an unborn child via telemedicine abortion. That is not going to happen in South Dakota.”
Under Executive Order 2021-12, abortion drugs can only be prescribed and dispensed to a woman by physicians licensed in South Dakota after the woman has undergone an in-person examination.
Noem’s executive order also prohibits women from obtaining abortion drugs by “courier, delivery, telemedicine, or mail service” and prohibits the drugs from being provided in schools and on state grounds.
The South Dakota governor also directed the Department of Health to create licensing requirements for “pill only” abortion clinics and gather data on how often women use abortion drugs and how often complications occur.
The pro-life Susan B. Anthony List praised Noem’s “bold” actions in a Tuesday statement, commending the governor for setting a “courageous model” that the organization hopes other state leaders will follow.
“The Biden administration would turn every post office and pharmacy into an abortion center if they had their way, leaving women alone and at risk of severe heavy bleeding, physical, emotional, and psychological stress, and more,” Susan B. Anthony List President Marjorie Dannenfelser said. “States must take action.”
“This is no longer about ‘a woman and her doctor,’ but a woman—or girl—and a stranger on the internet,” Catherine Glenn Foster, president and CEO of Americans United for Life, said in a separate statement. “States can no longer depend on the [Food and Drug Administration] to regulate abortion drugs in any meaningful way, and I am pleased to see Governor Noem step up for her state.”
“Abortion is never safe, but it’s far more dangerous when women are abandoned by physicians and left to manage their complications alone,” she added
In April, President Joe Biden’s administration announced it was lifting the Food and Drug Administration’s previous restrictions on abortion drugs, allowing the abortion pills to be delivered by mail during the coronavirus pandemic.
The Supreme Court had backed former President Donald Trump’s policy in January that the pills could not be dispensed by mail during the COVID-19 pandemic. But acting Food and Drug Administration Commissioner Janet Woodcock said in April that sending the drugs by mail will not increase risks for women and will protect those from COVID-19 who want the drugs.
The American College of Obstetricians and Gynecologists challenged the Trump administration’s requirement shortly after the death of Supreme Court Justice Ruth Bader Ginsberg, but the court declined to intervene, allowing abortion clinics to continue administering the drugs remotely, according to Politico.
The justices in January granted the Trump administration’s request that the rules be reinstated in a 6-3 decision.
The Food and Drug Administration had approved the use of the abortion drug mifepristone, also called Mifeprex, in 2000 for up to 10 weeks’ gestation. But the Food and Drug Administration explicitly warned that buyers should not purchase Mifeprex over the internet “because they will bypass important safeguards designed to protect their health.”
The Food and Drug Administration updated its website in April to note that it conducted a “careful scientific review” of both in-person and by-mail dispensing of the drugs, “either by or under the supervision of a certified prescriber, or through a mail-order pharmacy when such dispensing is done under the supervision of a certified prescriber.”
“The [Food and Drug Administration’s] intent to exercise enforcement discretion with respect to these requirements during the public health emergency is the result of a thorough scientific review by experts within [Food and Drug Administration’s] Center for Drug Evaluation and Research, who evaluated relevant information, including available clinical outcomes data and adverse event reports,” the Food and Drug Administration’s website said.
The Food and Drug Administration did not respond to requests for comment from The Daily Caller News Foundation.
Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities for this original content, email licensing@dailycallernewsfoundation.org.
Have an opinion about this article? To sound off, please email letters@DailySignal.com and we’ll consider publishing your edited remarks in our regular “We Hear You” feature. Remember to include the URL or headline of the article plus your name and town and/or state.